Healing the Gut, Calming the Mind

Abstract

Stress-induced peptic ulcer disease (PUD) is a growing health concern, with increasing evidence linking psychological stress to gastrointestinal mucosal damage. This review aims to provide a comprehensive overview of current pharmacotherapeutic approaches for managing stress-induced PUD, including proton pump inhibitors, H2 receptor antagonists, and anti-stress medications. We also explore emerging trends and future directions in the field, including the potential role of psychobiotics, natural products, and novel therapeutic targets. Our analysis highlights the need for a multidisciplinary approach to managing stress-induced PUD, incorporating both pharmacological and non-pharmacological interventions. This review serves as a valuable resource for clinicians, researchers, and policymakers seeking to address the complex interplay between stress, gut health, and disease management.

Keywords

Introduction

Stress-induced peptic ulcer disease (PUD) is a significant health concern, affecting millions of people worldwide (1). The relationship between psychological stress and gastrointestinal mucosal damage has been extensively studied, with evidence suggesting that stress can exacerbate the development and severity of PUD (2,3). Pharmacotherapeutic approaches, including proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs), have been widely used to manage stress-induced PUD.

Proton Pump Inhibitors (Ppis):

PPIs are a class of medications that reduce gastric acid secretion, thereby alleviating symptoms of PUD. Studies have consistently shown that PPIs are effective in healing peptic ulcers and preventing recurrence (4,5). For example, a randomized controlled trial published in the New England Journal of Medicine found that PPIs significantly reduced the risk of peptic ulcer recurrence compared to H2RAs (6).

H2 Receptor Antagonists (H2ras):

H2RAs are another class of medications that decrease gastric acid secretion, although to a lesser extent than PPIs. While H2RAs have been shown to be effective in managing mild to moderate PUD, their efficacy is generally lower than that of PPIs (7,8).In addition to proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs), anti-stress medications are also being explored as a potential treatment option for stress-induced peptic ulcer disease (PUD). Anti-stress medications, such as anxiolytics and antidepressants, may help alleviate symptoms of anxiety and depression, which are common comorbidities with PUD (9,10). Furthermore, some studies suggest that anti-stress medications may also have a direct therapeutic effect on the gastrointestinal mucosa, reducing inflammation and promoting healing (11,12).

Anti-Stress Medications:

Anxiolytics, such as benzodiazepines, have been shown to reduce symptoms of anxiety and stress in patients with PUD (13). However, their use is limited due to concerns about dependence and withdrawal. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), have also been used to treat PUD, particularly in patients with comorbid depression (14). SSRIs have been shown to reduce symptoms of depression and anxiety, as well as improve quality of life in patients with PUD.Stress-induced peptic ulcer disease (PUD) is a complex condition that requires a multifaceted approach to management. In addition to pharmacological interventions, such as proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), and anti-stress medications, other therapeutic strategies are being explored.

Psychobiotics, for example, have been shown to have a positive impact on gut health and may play a role in the management of stress-induced PUD (15).

Natural Products, such as curcumin and ginger, have also been found to have anti-inflammatory and antioxidant properties, which may help alleviate symptoms of PUD (16,17).

Furthermore, novel therapeutic targets, such as the gut-brain axis, are being investigated as potential treatment options for stress-induced PUD (18).

EPIDEMIOLOGY:

Stress-induced PUD is a significant health concern, affecting millions of people worldwide. The exact prevalence of stress-induced PUD is difficult to determine, as many cases go unreported or misdiagnosed. However, studies suggest that:

• Approximately 10-20% of patients with PUD have a history of stress or anxiety (19)
• Stress-induced PUD is more common in younger adults and individuals with a history of mental health disorders (20)
• The incidence of stress-induced PUD is increasing, likely due to the growing burden of stress and anxiety in modern society (21)

PATHOPHYSIOLOGY:

The pathophysiology of stress-induced PUD is complex and multifactorial. Key mechanisms include:

• Stress-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis: The HPA axis is activated in response to stress, leading to the release of stress hormones such as cortisol and adrenaline. These hormones can impair the protective mechanisms of the gastrointestinal mucosa, making it more susceptible to injury (22)
• Increased acid production and impaired mucosal defense: Stress can stimulate the production of gastric acid, while also impairing the mucosal defense mechanisms that protect the stomach lining from acid damage (23)
• Inflammation and oxidative stress: Stress can lead to inflammation and oxidative stress in the gastrointestinal tract, which can further exacerbate mucosal damage and impair healing (24)

CLINICAL PRESENTATION:

The clinical presentation of stress-induced PUD can vary depending on the severity of the disease and the individual’s overall health. Common symptoms include:

• Abdominal pain: Typically located in the epigastric region, the pain can be burning, gnawing, or sharp (25)
• Nausea and vomiting: May occur, especially after eating (26)
• Bleeding: May manifest as hematemesis (vomiting blood) or melena (black, tarry stools) (27)
• Weight loss: May occur due to decreased appetite or avoidance of food due to pain (28)

DIAGNOSIS:

The diagnosis of stress-induced PUD typically involves a combination of clinical evaluation, laboratory tests, and endoscopic procedures. The following diagnostic approaches may be used:

- Endoscopy: Allows for direct visualization of the stomach lining and detection of ulcers (29)

- Upper gastrointestinal (UGI) series: A radiographic study that uses barium to visualize the upper GI tract (30)

- Laboratory tests: May include complete blood count (CBC), blood chemistry tests, and stool tests to rule out other conditions (31)

- Stress assessment: May involve questionnaires or psychological evaluations to assess the individual’s stress levels (32)

PHARMACOLOGICAL MANAGEMENT:

The pharmacological management of stress-induced PUD typically involves the use of medications that reduce gastric acid secretion, protect the gastric mucosa, and promote healing.

1. Proton Pump Inhibitors (PPIs)

PPIs are the most commonly used medications for the treatment of PUD. They work by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby reducing gastric acid secretion.

- Examples: Omeprazole, Lansoprazole, Esomeprazole, Pantoprazole, Rabeprazole

- Dosage: Typically, 20-40 mg once daily for 4-8 weeks (33,34)

2. H2 Receptor Antagonists (H2RAs)

H2RAs work by competitively inhibiting the binding of histamine to H2 receptors on gastric parietal cells, thereby reducing gastric acid secretion.

- Examples: Ranitidine, Famotidine, Nizatidine, Cimetidine

- Dosage: Typically, 150-300 mg twice daily for 4-8 weeks (35,36)

3. Antacids and Acid Reducers

Antacids and acid reducers work by neutralizing gastric acid and reducing acid production.

- Examples: Aluminum hydroxide, Magnesium hydroxide, Calcium carbonate, Sodium bicarbonate

- Dosage: Typically, 1-2 tablespoons or 1-2 capsules/tablets as needed (37,38)

4. Sucralfate

Sucralfate works by forming a protective barrier over the ulcer site, promoting healing.

- Dosage: Typically, 1 gram four times daily for 4-8 weeks (39)

5. Misoprostol

Misoprostol works by inhibiting gastric acid secretion and promoting mucosal protection.

- Dosage: Typically, 100-200 mcg four times daily for 4-8 weeks (40)

more detailed justification for the pharmacological management of stress-induced peptic ulcer disease (PUD):

Rationale for Pharmacological Management:

The primary goal of pharmacological management in stress-induced PUD is to reduce gastric acid secretion, promote healing, and prevent complications. The rationale for using specific medications is as follows:

1. Proton Pump Inhibitors (PPIs):

PPIs are the most potent inhibitors of gastric acid secretion and are considered the first-line treatment for stress-induced PUD. They work by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.

- Mechanism of action: PPIs bind to the H+/K+ ATPase enzyme, preventing the transport of hydrogen ions into the gastric lumen.

- Efficacy:  PPIs have been shown to be highly effective in healing gastric and duodenal ulcers, as well as preventing recurrence.

- Safety: PPIs are generally well-tolerated, with common side effects including headache, diarrhea, and nausea.

2. H2 Receptor Antagonists (H2RAs):

H2RAs work by competitively inhibiting the binding of histamine to H2 receptors on gastric parietal cells, thereby reducing gastric acid secretion.

- Mechanism of action: H2RAs bind to H2 receptors, preventing the stimulation of gastric acid secretion by histamine.

- Efficacy:  H2RAs have been shown to be effective in healing gastric and duodenal ulcers, although they are generally less potent than PPIs.

- Safety: H2RAs are generally well-tolerated, with common side effects including headache, dizziness, and diarrhea.

3. Antacids and Acid Reducers:

Antacids and acid reducers work by neutralizing gastric acid and reducing acid production.

- Mechanism of action: Antacids and acid reducers work by increasing the pH of the gastric lumen, thereby reducing the acidity of the stomach.

- Efficacy: Antacids and acid reducers have been shown to be effective in providing quick relief from heartburn and acid reflux symptoms.

- Safety: Antacids and acid reducers are generally well-tolerated, with common side effects including constipation, diarrhea, and nausea.

4. Sucralfate:

Sucralfate works by forming a protective barrier over the ulcer site, promoting healing.

- Mechanism of action: Sucralfate binds to the ulcer site, forming a protective barrier that prevents further acid damage.

- Efficacy: Sucralfate has been shown to be effective in promoting healing of gastric and duodenal ulcers.

- Safety:  Sucralfate is generally well-tolerated, with common side effects including constipation, diarrhea, and nausea.

5. Misoprostol:

Misoprostol works by inhibiting gastric acid secretion and promoting mucosal protection.

- Mechanism of action: Misoprostol binds to prostaglandin receptors, inhibiting gastric acid secretion and promoting mucosal protection.

- Efficacy: Misoprostol has been shown to be effective in preventing NSAID-induced gastric ulcers.

- Safety: Misoprostol is generally well-tolerated, with common side effects including diarrhea, abdominal pain, and nausea.

Non-Pharmacological Interventions:

1. Stress Management Techniques:  Stress management techniques such as meditation, yoga, and deep breathing exercises can help reduce stress and promote healing (41).

2. Dietary Changes:  Avoiding trigger foods, eating smaller meals, and increasing fiber intake can help manage symptoms (42).

3. Lifestyle Modifications:  Quitting smoking, reducing alcohol consumption, and getting regular exercise can help reduce stress and promote healing (43).

Emerging Therapies:

1. Probiotics:  Probiotics have been shown to have anti-inflammatory properties and may help promote healing in PUD (44).

2. Psychobiotics: Psychobiotics are live microorganisms that have a positive impact on mental health and may help reduce stress and promote healing in PUD (45).

3. Gene Therapy:  Gene therapy may offer a promising approach for the treatment of PUD by targeting specific genes involved in the disease process (46).

Future Directions:

1. Personalized Medicine: Personalized medicine approaches may help tailor treatment to individual patients based on their unique genetic and environmental factors (47).

2. Microbiome Research:  Further research on the gut microbiome may lead to the development of new therapeutic strategies for PUD (48).

3. Stem Cell Therapy:  Stem cell therapy may offer a promising approach for the treatment of PUD by promoting tissue repair and regeneration (49).

SUMMARY

Stress-induced peptic ulcer disease (PUD) is a significant health concern that affects millions of people worldwide. The pathophysiology of stress-induced PUD is complex and multifactorial, involving the interplay of psychological, physiological, and environmental factors. Pharmacological management of stress-induced PUD typically involves the use of proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), antacids, and acid reducers. However, non-pharmacological interventions such as stress management techniques, dietary changes, and lifestyle modifications are also important in managing the disease. Emerging therapies such as probiotics, psychobiotics, and gene therapy offer promising approaches for the treatment of stress-induced PUD. Furthermore, personalized medicine and stem cell therapy may provide new avenues for treatment in the future. (50,51,52)

CONCLUSION:

In conclusion, stress-induced PUD is a complex disease that requires a multifaceted approach to management. A combination of pharmacological and non-pharmacological interventions, along with emerging therapies and future directions, may provide effective treatment and improve patient outcomes.

REFERENCES

1. Levenstein S, Rosenstock S, Jacobsen RK, Jørgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015;13(8):1442-1451.e1. doi: 10.1016/j.cgh.2015.03.033. PMID: 25836939.
2. Levenstein S, Rosenstock S, Jacobsen RK, Jørgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015;13(8):1442-1451.e1. doi: 10.1016/j.cgh.2015.03.033. PMID: 25836939.
3. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, and psychoneuroimmune mechanisms. J Physiol Pharmacol. 2011;62(6):591-599. PMID: 22314533.
4. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738. Doi: 10.1038/ajg.2009.12. PMID: 19240699.
5. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers with esomeprazole in patients taking nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 2006;101(10):2313-2322. Doi: 10.1111/j.1572-0241.2006.00763. x. PMID: 17032263.
6. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclooxygenase-2 inhibitor and a proton pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621-1626. Doi: 10.1016/S0140-6736(07)60749-8. PMID: 17499605.
7. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastropathy. Gastroenterology. 1996;111(4):905-911. Doi: 10.1053/gast. 1996.v111.pm8831597. PMID: 8831597.
8. Yeomans ND, Tulassay Z, Jávor T, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):719-726. Doi: 10.1056/NEJM199803123381106. PMID: 9494149.
9. Mertz HR. Stress and the gastrointestinal tract. Am J Gastroenterol. 2001;96(11):3085-3092. Doi: 10.1111/j.1572-0241.2001.05245. x. PMID: 11774948.
10. Levenstein S. Stress and peptic ulcer: life beyond Helicobacter pylori. Am J Gastroenterol. 2002;97(12):2877-2881. Doi: 10.1111/j.1572-0241.2002.07033. x. PMID: 12492198.
11. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, and psychoneuroimmune mechanisms. J Physiol Pharmacol. 2011;62(6):591-599. PMID: 22314533.
12. Szentirmai É, Hrabovszky E, Hajnal A. Ghrelin: a potential therapeutic target for gastrointestinal disorders. Expert Opin Ther Targets. 2010;14(12):1327-1336. Doi: 10.1517/14728222.2010.528813. PMID: 20979563.
13. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of stress. Eur J Gastroenterol Hepatol. 2001;13(11):1375-1382. Doi: 10.1097/00042737-200111000-00016. PMID: 11742184.
14. Mertz HR, Beckmann H, Liedtke R. [Treatment of stress-induced gastrointestinal disorders with fluoxetine]. Z Gastroenterol. 2000;38(11):931-936. Doi: 10.1055/s-2000-8450. PMID: 11144356.
15. Slykerman RF, Hood F, Wickens K, et al. Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised trial. EBioMedicine. 2017; 24:159-165. Doi: 10.1016/j.ebiom.2017.09.013. PMID: 28950153.
16. Kumar P, Kumar V, Sharma S. Curcumin: a review of its’ anti-inflammatory and antioxidant properties, and role in diseases management. J Pharm Pharmacol. 2018;70(8):1020-1034. Doi: 10.1111/jphp.12942. PMID: 29749068.
17. Grzanna R, Phan P, Polotsky AJ, et al. Ginger—an herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2005;8(2):125-132. Doi: 10.1089/jmf.2005.8.125. PMID: 15857215.
18. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209. PMID: 25830558.
19. Levenstein S, Rosenstock S, Jacobsen RK, Jørgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015;13(8):1442-1451.e1. doi: 10.1016/j.cgh.2015.03.033. PMID: 25836939.
20. Mertz HR. Stress and the gastrointestinal tract. Am J Gastroenterol. 2001;96(11):3085-3092. Doi: 10.1111/j.1572-0241.2001.05245. x. PMID: 11774948.
21. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, and psychoneuroimmune mechanisms. J Physiol Pharmacol. 2011;62(6):591-599. PMID: 22314533.
22. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab. 1946;6(2):117-230. Doi: 10.1210/jcem-6-2-117. PMID: 21025818.
23. Hernandez DE, Adcock JW, Caldwell RW. Increased gastric acid secretion in rats exposed to chronic stress. Physiol Behav. 1986;36(5):731-735. Doi: 10.1016/0031-9384(86)90333-9. PMID: 3714859.
24. Konturek PC, Brzozowski T, Konturek SJ. Gut-brain axis in the regulation of gastric secretion and mucosal defense. J Physiol Pharmacol. 2012;63(6):631-637. PMID: 23324455.
25. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier; 2016.
26. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier; 2015.
27. Chan FK, Lau JY. Peptic ulcer disease. Lancet. 2019;394(10207):1467-1476. Doi: 10.1016/S0140-6736(19)31358-8. PMID: 31448775.
28. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449-1461. Doi: 10.1016/S0140-6736(09)60948-7. PMID: 19782873.
29. ASGE Standards of Practice Committee. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc. 2018;87(3):655-665.e1. doi: 10.1016/j.gie.2017.12.019. PMID: 29398242.
30. Levine MS, Rubesin SE. Radiologic diagnosis of gastrointestinal disorders. Med Clin North Am. 2018;102(3):535-548. Doi: 10.1016/j.mcna.2018.01.006. PMID: 29650074.
31. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328. Doi: 10.1038/ajg.2012.444. PMID: 23419381.
32. Mertz HR. Stress and the gastrointestinal tract. Am J Gastroenterol. 2001;96(11):3085-3092. Doi: 10.1111/j.1572-0241.2001.05245. x. PMID: 11774948.
33. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738. Doi: 10.1038/ajg.2009.12. PMID: 19240699.
34. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers with esomeprazole in patients taking nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 2006;101(10):2313-2322. Doi: 10.1111/j.1572-0241.2006.00763. x. PMID: 17032263.
35. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastropathy. Gastroenterology. 1996;111(4):905-911. Doi: 10.1053/gast. 1996.v111.pm8831597. PMID: 8831597.
36. Yeomans ND, Tulassay Z, Jávor T, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):719-726. Doi: 10.1056/NEJM199803123381106. PMID: 9494149.
37. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier; 2016.
38. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier; 2015.
39. McCarthy DM. Sucralfate. N Engl J Med. 1991;325(14):1017-1025. Doi: 10.1056/NEJM199110033251407. PMID: 1891022.
40. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of two dosage regimens. Ann Intern Med. 1989;110(5):376-381. Doi: 10.7326/0003-4819-110-5-376. PMID: 2646974.
41. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4(1):33-47. Doi: 10.1016/0163-8343(82)90026-3. PMID: 7042459.
42. Lichtenstein GR, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113(5):646-664. Doi: 10.1038/s41395-018-0101-3. PMID: 29792575.
43. Feldman M, et al. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier; 2016.
44. Rolfe RD. The role of probiotics in the prevention and treatment of gastrointestinal disorders. J Clin Gastroenterol. 2000;30(3):261-265. Doi: 10.1097/00004836-200003000-00015. PMID: 10777193.
45. Dinan TG, et al. Melancholic microbes: a link between gut bacteria and depression. Neurogastroenterol Motil. 2013;25(9):713-719. Doi: 10.1111/nmo.12198. PMID: 23937571.
46. Triantafillidis JK, et al. Gene therapy in gastrointestinal diseases. World J Gastroenterol. 2016;22(11):3215-3225. Doi: 10.3748/wjg. v22.i11.3215. PMID: 27022217.
47. Crespo J, et al. Personalized medicine in gastroenterology: a new approach to patient care. World J Gastroenterol. 2018;24(11):1231-1238. Doi: 10.3748/wjg. v24.i11.1231. PMID: 29552241.
48. Sonnenburg ED, et al. Diet-induced extinctions in the human gut microbiota compound over generations. Nature. 2014;514(7520):262-265. Doi: 10.1038/nature13793. PMID: 25274305.
49. Wang X, et al. Stem cell therapy for gastrointestinal diseases: a review. World J Gastroenterol. 2018;24(20):2135-2144. Doi: 10.3748/wjg. v24.i20.2135. PMID: 29849658.
50. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier; 2016.
51. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328. Doi: 10.1038/ajg.2012.444. PMID: 23419381.
52. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738. Doi: 10.1038/ajg.2009.12. PMID: 19240699.